Physician profile
Amit Agarwal
NPI 1568773117
$15,894.39
in general payments reported to CMS, 2019-2025
43 companies · $2,235 in 2025
The $2,235 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $2,169 · 2021: $2,333 · 2022: $2,504 · 2023: $2,618 · 2024: $2,812 · 2025: $2,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,633 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,632.71 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,793.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $2,474.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,609.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,559.86 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,190.23 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $867.64 | 2020-2025 | Ubrelvy, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $736.35 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $463.12 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $345.80 | 2020-2023 | Steglatro |
| Sanofi-Aventis U.S. LLC | $334.67 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $319.00 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $303.33 | 2019-2024 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $263.48 | 2019-2024 | |
| Esperion Therapeutics, INC. | $255.76 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $217.02 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.